- Conditions
- Urothelial Carcinoma
- Interventions
- MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV)
- Drug · Biological
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Irvine, California • Dallas, Texas • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2761–2784
of 50,397
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Diagnostic Test · Drug
- Lead sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Localized Skin Lesion, Mycosis Fungoides
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sarcoma, Soft Tissue Sarcoma
- Interventions
- Avastin, Doxorubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gastroesophageal-junction Cancer, Esophageal Cancer
- Interventions
- EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Decatur, Illinois • Park Ridge, Illinois + 4 more
- Conditions
- Myelofibrosis (MF)
- Interventions
- Mivebresib, Navitoclax, Ruxolitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more
- Conditions
- PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
- Interventions
- AMO959, AAA617, Enzalutamide, Abiraterone
- Drug · Radiation
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Durham, North Carolina • El Paso, Texas + 1 more
- Conditions
- Head and Neck Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Maastricht Radiation Oncology
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Estramustine, Vinorelbine
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Lymphocytic B-Leukemia
- Interventions
- Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Nicotinamide riboside, Placebo capsules
- Drug
- Lead sponsor
- Donna Hammond, PhD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Brain Stem Glioma, Glioblastoma
- Interventions
- autologous dendritic cells
- Biological
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphedema, Lymphedema of Upper Arm, Lymphedema, Breast Cancer
- Interventions
- Crossover Device (PCD or Dayspring - alternate to first group)
- Device
- Lead sponsor
- Koya Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Los Altos, California • Morgan Hill, California
- Conditions
- Breast Cancer, Breast Cancer and Pregnancy
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado + 1 more
- Conditions
- Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
- Interventions
- Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 49 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cixutumumab, temsirolimus, pharmacological study, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 17 more
- Conditions
- AL Amyloidosis
- Interventions
- NEOD001
- Drug
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
- Drug · Diagnostic Test · Other
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- AZD4045, Daratumumab, Aldesleukin
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 7 more
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- etaracizumab, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Marysville, California • Sacramento, California • Ann Arbor, Michigan + 2 more
- Conditions
- Moderate and Severe Plaque Psoriasis
- Interventions
- Placebo, AEB071
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 10
- States / cities
- Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more
- Conditions
- Cancers, Pain
- Interventions
- Telephone Care + Educational (AV Materials)
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Breast Neoplasm
- Interventions
- F-18 FES, F-18 FDG
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 90 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota